Equities Analysts Set Expectations for TPST FY2026 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Research analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Tempest Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now expects that the company will earn ($1.34) per share for the year, up from their previous estimate of ($2.76). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ FY2027 earnings at ($1.21) EPS and FY2028 earnings at ($0.89) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempest Therapeutics in a research report on Monday, December 29th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $12.50.

Tempest Therapeutics Price Performance

Shares of Tempest Therapeutics stock opened at $1.59 on Friday. The stock has a market cap of $7.83 million, a price-to-earnings ratio of -0.24 and a beta of -2.00. The firm’s 50-day moving average is $2.25 and its two-hundred day moving average is $5.00. Tempest Therapeutics has a 1 year low of $1.50 and a 1 year high of $12.23.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.62) EPS for the quarter, meeting the consensus estimate of ($0.62).

Insiders Place Their Bets

In other Tempest Therapeutics news, CEO Matthew Angel purchased 231,482 shares of the stock in a transaction that occurred on Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the completion of the transaction, the chief executive officer owned 231,482 shares of the company’s stock, valued at $500,001.12. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 6.28% of the company’s stock.

Institutional Trading of Tempest Therapeutics

A number of hedge funds have recently bought and sold shares of TPST. Dimensional Fund Advisors LP purchased a new position in Tempest Therapeutics in the 4th quarter worth approximately $33,000. Sabby Management LLC purchased a new stake in shares of Tempest Therapeutics in the fourth quarter valued at approximately $513,000. Finally, Vanguard Group Inc. grew its position in shares of Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after purchasing an additional 27,952 shares in the last quarter. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.